Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
McKinsey
Healthtrust
Harvard Business School
Boehringer Ingelheim
UBS
Moodys
Farmers Insurance
Federal Trade Commission
Merck

Generated: October 21, 2017

DrugPatentWatch Database Preview

VISTOGARD Drug Profile

« Back to Dashboard

Which patents cover Vistogard, and what generic Vistogard alternatives are available?

Vistogard is a drug marketed by Wellstat Therap and is included in one NDA. There are three patents protecting this drug.

This drug has one hundred and seventy-five patent family members in twenty-one countries and two supplementary protection certificates in two countries.

The generic ingredient in VISTOGARD is uridine triacetate. There are thirty-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the uridine triacetate profile page.

Summary for Tradename: VISTOGARD

US Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:VISTOGARD at DailyMed

Pharmacology for Tradename: VISTOGARD

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wellstat Therap
VISTOGARD
uridine triacetate
GRANULE;ORAL208159-001Dec 11, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Wellstat Therap
VISTOGARD
uridine triacetate
GRANULE;ORAL208159-001Dec 11, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Wellstat Therap
VISTOGARD
uridine triacetate
GRANULE;ORAL208159-001Dec 11, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Wellstat Therap
VISTOGARD
uridine triacetate
GRANULE;ORAL208159-001Dec 11, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Wellstat Therap
VISTOGARD
uridine triacetate
GRANULE;ORAL208159-001Dec 11, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Wellstat Therap
VISTOGARD
uridine triacetate
GRANULE;ORAL208159-001Dec 11, 2015RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: VISTOGARD

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Wellstat Therap
VISTOGARD
uridine triacetate
GRANULE;ORAL208159-001Dec 11, 2015► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: VISTOGARD

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,736,531 Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides► Subscribe
6,329,350 Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis► Subscribe
6,306,834 Acyl deoxyribonucleoside derivatives and uses thereof► Subscribe
6,274,563 Acylated uridine and cytidine and uses thereof► Subscribe
6,348,451 Acyl deoxyribonucleoside derivatives and uses thereof► Subscribe
5,246,708 Methods for promoting wound healing with deoxyribonucleosides► Subscribe
6,020,322 Acyl deoxyribonucleoside derivatives and uses thereof► Subscribe
7,166,581Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides► Subscribe
7,709,459Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis► Subscribe
6,743,782 Acyl deoxyribonucleoside derivatives and uses thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: VISTOGARD

Country Document Number Estimated Expiration
Israel100874► Subscribe
South Africa8902928► Subscribe
Hong Kong1004854► Subscribe
World Intellectual Property Organization (WIPO)9604923► Subscribe
European Patent Office0594667► Subscribe
European Patent Office0570519► Subscribe
Austria205850► Subscribe
Japan2003160585► Subscribe
Japan2009167213► Subscribe
Hong Kong1005703► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: VISTOGARD

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2017 00036Denmark► SubscribePRODUCT NAME: TRIFLURIDINE IN COMBINATION WITH TIPIRACIL OR A PHARMACEUTICALLY ACCEPTABLE SALT OF TIPIRACIL; REG. NO/DATE: EU/1/16/1096 20160427
0889Netherlands► SubscribePRODUCT NAME: TRIFLURIDINE IN COMBINATIE MET TIPIRACIL OF EEN ZOUT VAN TIPIRACIL, ZOALS TIPIRACILHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/16/1096 20160427
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Mallinckrodt
Baxter
Chinese Patent Office
Covington
Julphar
Novartis
McKesson
Colorcon
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot